Great news? Pain relief
Posted: Wed Jan 14, 2004 7:53 pm
YEAH! thanks for posting this, I ahve been wondering about it!
COurt
United Brachial Plexus Network, Inc.
Great news? Pain relief
Page 1 of 1
Re: Great news? Pain relief
Posted: Thu Jan 15, 2004 11:38 am
Re: Great news? Pain relief
Posted: Thu Jan 15, 2004 2:08 pm
Can someone tell me if we can buy this drug?
Someone is using it already?
Pleas provide the forum more information about it….
I am very excited about snail venom and I am wondering
If I can do small test at home with rattle snake….
)))))))))
Someone is using it already?
Pleas provide the forum more information about it….
I am very excited about snail venom and I am wondering
If I can do small test at home with rattle snake….
)))))))))Re: Great news? Pain relief
Posted: Fri Apr 09, 2004 8:47 am
Ziconotide (SNX-111)
Tried asking my Pain Clinic Doctor at USC about this yesterday, and he didn't seem to know much about it. So I'm trying to do some research on my own. Seems like it can only be administered by direct input into the spinal cord and would have to be constantly released by a pump.
Below I've pasted a clip from the drug company's website:
http://docmd.com/ziconotide/index.asp
Brose WG. Gutlove DP. Luther RR. Bowersox SS. McGuire D. Use of intrathecal ziconotide (SNX-111), a novel, N-type, voltage-sensitive, calcium channel blocker, in the management of intractable brachial plexus avulsion pain. Clinical Journal of Pain. 13(3):256-9, 1997.
Case Summary
To study the analgesic, antihyperesthesic, and anti-allodynic properties of ziconotide (SNX-111) in neuropathic pain, the authors describe a patient with refractory, severe deafferentation pain successfully treated with SNX-111 in an open-label, baseline-controlled Phase I/II trial. The patient was a 43-year-old man with intractable deafferentation pain of 23 years' duration secondary to brachial plexus avulsion. Ziconotide, the first neuron-specific, N-type, voltage-sensitive calcium channel blocker developed for clinical use, was administered by continuous, constant-rate, intrathecal infusion via an indwelling cervical catheter. The primary outcome measures were the Visual Analog Scales of Pain Intensity (VASPI) and Pain Relief (VASPR). The patient experienced complete pain relief (VASPI = 0.0 cm and VASPR = 10.0 cm) with elimination of hyperesthesia and allodynia. The authors conclude that ziconotide (SNX-111) administered intrathecally by continuous, constant-rate infusion, produced dose-dependent pain relief in a 43-year-old male patient with a 23-year history of intractable deafferentation and phantom limb pain secondary to brachial plexus avulsion and subsequent amputation. Dizziness, blurred vision, and lateral-gaze nystagmus were dose-dependent side effects that resolved with decreasing dose levels. Complete pain relief was achieved in this patient without side effects after dose adjustment. They report that ziconotide (SNX-111) is a potent analgesic, antihyperesthesic, and antiallodynic agent.
I hope this stuff helps some of us SOON!
Christopher
Tried asking my Pain Clinic Doctor at USC about this yesterday, and he didn't seem to know much about it. So I'm trying to do some research on my own. Seems like it can only be administered by direct input into the spinal cord and would have to be constantly released by a pump.
Below I've pasted a clip from the drug company's website:
http://docmd.com/ziconotide/index.asp
Brose WG. Gutlove DP. Luther RR. Bowersox SS. McGuire D. Use of intrathecal ziconotide (SNX-111), a novel, N-type, voltage-sensitive, calcium channel blocker, in the management of intractable brachial plexus avulsion pain. Clinical Journal of Pain. 13(3):256-9, 1997.
Case Summary
To study the analgesic, antihyperesthesic, and anti-allodynic properties of ziconotide (SNX-111) in neuropathic pain, the authors describe a patient with refractory, severe deafferentation pain successfully treated with SNX-111 in an open-label, baseline-controlled Phase I/II trial. The patient was a 43-year-old man with intractable deafferentation pain of 23 years' duration secondary to brachial plexus avulsion. Ziconotide, the first neuron-specific, N-type, voltage-sensitive calcium channel blocker developed for clinical use, was administered by continuous, constant-rate, intrathecal infusion via an indwelling cervical catheter. The primary outcome measures were the Visual Analog Scales of Pain Intensity (VASPI) and Pain Relief (VASPR). The patient experienced complete pain relief (VASPI = 0.0 cm and VASPR = 10.0 cm) with elimination of hyperesthesia and allodynia. The authors conclude that ziconotide (SNX-111) administered intrathecally by continuous, constant-rate infusion, produced dose-dependent pain relief in a 43-year-old male patient with a 23-year history of intractable deafferentation and phantom limb pain secondary to brachial plexus avulsion and subsequent amputation. Dizziness, blurred vision, and lateral-gaze nystagmus were dose-dependent side effects that resolved with decreasing dose levels. Complete pain relief was achieved in this patient without side effects after dose adjustment. They report that ziconotide (SNX-111) is a potent analgesic, antihyperesthesic, and antiallodynic agent.
I hope this stuff helps some of us SOON!
Christopher